Trading Signals: RARE Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Fri. Oct. 27, 2023)(Ultragenyx Pharmaceutical Inc)
| RARE latest price $49.0400 (3.57%) ($49.0400 - $49.0400) on Fri. May. 20, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.05% (three month average) | RSI | 22 | Latest Price | $49.0400(3.57%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | RARE declines -0.9% a day on average for past five trading days. | Weekly Trend | RARE declines -13.4% a week on average for past two weeks. | Market Behavior | Normal for large cap. Normal for small cap. | Correlated ETFs | Broad market will support RARE advance at 0% a week (0% probability) IBB(55%) IWC(45%) IWO(45%) IWM(42%) IWN(39%) | Factors Impacting RARE price | RARE will decline at least -2.025% in a week (0% probabilities). VIXM(-21%) UUP(-11%) VXX(-8%) UNG(-7%) TBT(-6%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -2.025% (StdDev 4.05%) | Hourly BBV | 0.3 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $22.52(-54.08%) | Resistance Level | $59.78 | 5 Day Moving Average | $50.76(-3.39%) | 10 Day Moving Average | $51.13(-4.09%) | 20 Day Moving Average | $59.78(-17.97%) | To recent high | -42.4% | To recent low | 3.6% | Market Cap | $2.963b | | | | Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. Mepsevii is an intravenous, which is used for the treatment of Mucopolysaccharidosis VII. Crysvita is an antibody administered via subcutaneous injection used for the treatment of XLH. The company was founded by Emil D. Kakkis on April 22, 2010 and is headquartered in Novato, CA. |